Publication: Reduced immunogenicity of intraparenchymal delivery of adeno-associated virus serotype 2 vectors: Brief overview
This perspectives article, published in Current Gene Therapy, describes the low risk of immune response to adeno-associated virus serotype 2 (AAV2) vector-mediated gene therapy to the brain, with support from clinical trial data in aromatic L-amino acid decarboxylase (AADC) deficiency
Understand the role of pre-existing neutralizing antibodies and how they may impact the efficacy and safety of adeno-associated virus (AAV) vector-mediated gene therapy
Learn the differences between systemic and localized gene therapy and the features of different sites for gene therapy administration
Review clinical data from AAV2 vector-mediated gene therapy in AADC deficiency
Hwu WL, Muramatsu SI, Gidoni-Ben-Zeev B. Curr Gene Ther. 2021 Sep 22. Online ahead of print
Once registered, you will be able to view the abstract and be provided the DOI and PubMed links for this publication.
Eladocagene exuparvovec is an investigational gene therapy product currently being developed by PTC Therapeutics for the treatment of patients with deficiency of a protein called AADC. Eladocagene exuparvovec does not currently have a marketing authorization for the treatment of AADC deficiency.
Register now to unlock the content
Register now to access the content on this page
If not, register below
MED-ALL-AADC-2200023 | March 2022
Sign in or register to access exclusive content on this site
Some cookies are essential, others help us improve your experience by providing insights into how the website is used. Select one or more of the cookie types listed below, and then save your preferences. Refer to our Cookies Statement for more information.
Performance cookies, which help us measure the website’s performance and improve your experience. In using performance cookies we do not store any personal data, and only use the information collected through these cookies in aggregated and anonymised form.